Mechanism of action
Pentobarbital acts as a positive allosteric modulator of the GABA_A receptor, the major inhibitory neurotransmitter receptor in the central nervous system. Unlike benzodiazepines, which increase the frequency of chloride channel opening, barbiturates like pentobarbital prolong the duration of chloride channel opening. At higher concentrations, pentobarbital can directly activate GABA_A receptors even in the absence of GABA, which explains its greater potential for profound CNS depression and respiratory arrest compared to benzodiazepines.
Pentobarbital also decreases excitatory glutamate signaling by blocking AMPA receptors at therapeutic concentrations. This dual mechanism—enhancing inhibition and reducing excitation—makes it effective for refractory seizures and therapeutic coma induction. The drug decreases cerebral metabolic rate, cerebral blood flow, and intracranial pressure, which is exploited in the management of traumatic brain injury with elevated ICP refractory to other measures.
- Pentobarbital prolongs GABA_A chloride channel opening duration (vs. benzodiazepines, which increase frequency).
- Barbiturates can directly activate GABA_A receptors at high doses, causing greater respiratory depression than benzodiazepines.
- Absolutely contraindicated in acute porphyria (induces ALA synthase, triggering attacks).
- Potent CYP450 inducer: decreases efficacy of warfarin, oral contraceptives, and many anticonvulsants.
- Barbiturate withdrawal resembles alcohol withdrawal: tremor, seizures, delirium; taper slowly or substitute phenobarbital.
- Used for refractory status epilepticus with continuous EEG monitoring to achieve burst suppression.
- No reversal agent for barbiturate overdose; flumazenil is ineffective (works only on benzodiazepines).
- Schedule II controlled substance; high potential for dependence and lethal overdose.
Indications
Pentobarbital has limited but important clinical uses:
- Refractory status epilepticus: pentobarbital coma is a third-line or fourth-line option when seizures persist despite benzodiazepines, levetiracetam, and other anticonvulsants. EEG monitoring is required to titrate to burst suppression.
- Therapeutic coma for elevated intracranial pressure: used in traumatic brain injury or other causes of cerebral edema when ICP remains elevated despite osmotic agents, hyperventilation, and surgical interventions.
- Medically assisted death: pentobarbital is used in physician-assisted suicide and euthanasia in jurisdictions where these practices are legal, owing to its ability to induce rapid, painless unconsciousness followed by respiratory arrest.
- Historical uses: formerly used for sedation before procedures, preanesthetic sedation, and insomnia; these indications have been largely supplanted by safer agents such as benzodiazepines and propofol.
Pentobarbital is a Schedule II controlled substance in the United States due to its potential for abuse, dependence, and diversion.
Pharmacokinetics
Pentobarbital is highly lipophilic, leading to rapid onset when administered intravenously (within 1 minute) and quick redistribution from the brain to peripheral tissues, which terminates the initial effect within 15–30 minutes after a single dose. The elimination half-life is approximately 20–50 hours but is highly variable and prolonged in critically ill patients.
The drug is metabolized primarily by the liver via cytochrome P450 enzymes, particularly CYP2C19 and CYP3A4. Pentobarbital is a potent inducer of hepatic enzymes, accelerating the metabolism of many drugs, including itself (autoinduction), warfarin, oral contraceptives, corticosteroids, and many anticonvulsants. Renal excretion of unchanged drug is minimal.
Protein binding is approximately 35–45%, and the volume of distribution is large. In patients with hepatic impairment, clearance is reduced and the half-life prolonged, necessitating careful titration. Pentobarbital crosses the placenta and is excreted in breast milk.
Adverse effects
Pentobarbital carries significant risks, particularly with repeated or high-dose use:
Central nervous system
- CNS depression: sedation, lethargy, confusion, ataxia, and cognitive impairment
- Paradoxical excitation or agitation, especially in children and the elderly
- Tolerance develops rapidly with repeated use
Respiratory
- Respiratory depression is dose-dependent and potentially fatal; risk is highest when combined with other CNS depressants (opioids, benzodiazepines, alcohol)
- Apnea with intravenous bolus dosing
Cardiovascular
- Hypotension due to decreased sympathetic tone and myocardial depression
- Bradycardia
Dependence and withdrawal
- Physical and psychological dependence develop with chronic use
- Withdrawal syndrome can be severe and life-threatening, resembling alcohol withdrawal: anxiety, tremor, seizures, delirium, and autonomic instability
- Withdrawal seizures typically occur 1–3 days after cessation
Hematologic
- Rare: megaloblastic anemia (folate deficiency from enzyme induction)
Dermatologic
- Rash, including Stevens-Johnson syndrome (rare)
Hepatic
- Hepatic enzyme induction leading to drug interactions
Other
- Porphyria exacerbation: barbiturates induce ALA synthase and can precipitate acute attacks in patients with acute intermittent porphyria
Contraindications and warnings
Absolute contraindications:
- Porphyria (acute intermittent porphyria, variegate porphyria, hereditary coproporphyria): barbiturates induce ALA synthase and can trigger potentially fatal acute attacks
- History of barbiturate hypersensitivity
- Severe respiratory insufficiency without mechanical ventilatory support
Relative contraindications and warnings:
- Pregnancy: pentobarbital crosses the placenta and is associated with fetal harm, including neonatal dependence and withdrawal. Use only if the benefit clearly outweighs the risk. Category D.
- Breastfeeding: excreted in breast milk; may cause sedation or withdrawal in the infant
- Hepatic impairment: reduced clearance and prolonged effect
- Renal impairment: active metabolites may accumulate
- Elderly: increased sensitivity to CNS and respiratory depression
- Suicidal ideation: barbiturate overdose is highly lethal; limit access in at-risk patients
- Chronic use: tolerance, dependence, and withdrawal risk
Pentobarbital should be administered only in settings with full resuscitation equipment and personnel trained in airway management.
Drug interactions
Pentobarbital has numerous clinically important interactions:
CNS depressants
- Additive CNS and respiratory depression with opioids, benzodiazepines, alcohol, propofol, other sedative-hypnotics, first-generation antihistamines, and antipsychotics. Increased risk of fatal respiratory arrest.
Enzyme induction
Pentobarbital induces CYP2C9, CYP2C19, and CYP3A4, reducing the efficacy of:
- Warfarin: increased metabolism, reduced anticoagulant effect
- Oral contraceptives: decreased efficacy, risk of unintended pregnancy
- Corticosteroids: reduced systemic exposure
- Phenytoin, carbamazepine, lamotrigine: decreased levels (though phenytoin may also induce pentobarbital metabolism)
- Doxycycline: reduced efficacy
- Theophylline: increased clearance
- Protease inhibitors and NNRTIs: reduced antiretroviral effect
Valproic acid
- Valproate inhibits pentobarbital metabolism, increasing pentobarbital levels and risk of toxicity
MAO inhibitors
- Prolonged CNS depression when combined with barbiturates
Griseofulvin
- Pentobarbital reduces griseofulvin absorption
Clinical pearl: always review and adjust concomitant medications when initiating or discontinuing pentobarbital.
Clinical pearls
- Barbiturates vs. benzodiazepines: barbiturates prolong chloride channel opening duration; benzodiazepines increase opening frequency. Barbiturates can directly activate GABA_A receptors at high doses, leading to greater toxicity and no ceiling effect for respiratory depression. Benzodiazepines are safer.
- Refractory status epilepticus: pentobarbital coma is typically reserved for cases failing midazolam or propofol infusions. Continuous EEG monitoring is mandatory; the goal is burst suppression. Hypotension requiring vasopressors is common.
- Enzyme induction: onset of induction occurs within days and persists for weeks after discontinuation. Always check for interactions with oral contraceptives, warfarin, and antiretrovirals.
- Withdrawal management: barbiturate withdrawal is medically serious and resembles alcohol withdrawal. Taper slowly (10% dose reduction every few days) or substitute phenobarbital (longer half-life, easier to taper). Abrupt cessation can be fatal.
- Overdose: presents with CNS depression, respiratory failure, hypothermia, hypotension, and areflexia. Pupils may be miotic or midposition. There is no specific reversal agent (flumazenil does not work on barbiturates). Management is supportive: airway protection, mechanical ventilation, and vasopressor support.
- Porphyria: remember that barbiturates are absolutely contraindicated in acute porphyrias; they can precipitate a life-threatening attack.
- Forensic note: pentobarbital has been used in lethal injection protocols and veterinary euthanasia, which has led to supply restrictions and political controversy in some jurisdictions.
Barbiturates PROLONG the channel (vs. benzos which increase frequency): Prolong chloride opening, Respiratory depression (no ceiling), Overdose has no reversal, Liver enzyme induction, Onset rapid but redistributes, No use in porphyria, Gets you dependent quickly.
Practice questions
1. A 32-year-old woman with refractory status epilepticus is admitted to the ICU. After treatment with lorazepam, levetiracetam, and a midazolam infusion, seizures persist. The team initiates pentobarbital coma with continuous EEG monitoring. Two days later, her blood pressure drops to 82/50 mmHg despite adequate fluid resuscitation. What is the most likely explanation for her hypotension?
2. A 45-year-old man with a history of barbiturate dependence is hospitalized for pneumonia. Seventy-two hours after admission, he develops confusion, tremor, diaphoresis, and a generalized tonic-clonic seizure. Vital signs show BP 160/95 mmHg, HR 115/min, and temperature 38.2°C. Which of the following is the most appropriate initial management?
3. A 28-year-old woman with a history of acute intermittent porphyria presents to the emergency department with a severe migraine. The physician considers sedation options. Which of the following medications is absolutely contraindicated in this patient?
Frequently asked questions
How does pentobarbital work?
Pentobarbital enhances GABA_A receptor activity by prolonging the duration of chloride channel opening, which increases inhibitory neurotransmission in the brain. At higher doses, it can also directly activate GABA_A receptors independently of GABA. This dual effect provides potent CNS depression, sedation, and anticonvulsant activity, but also carries significant risk of respiratory depression and overdose.
What are the side effects of pentobarbital?
The most serious side effects are dose-dependent respiratory depression and CNS depression, which can lead to apnea and death, especially when combined with other sedatives or opioids. Other effects include hypotension, bradycardia, sedation, confusion, ataxia, and paradoxical agitation. Chronic use leads to tolerance, physical dependence, and a potentially life-threatening withdrawal syndrome. Pentobarbital also induces liver enzymes, causing numerous drug interactions.
Is pentobarbital a controlled substance?
Yes, pentobarbital is a Schedule II controlled substance in the United States, indicating high potential for abuse and dependence. It requires a DEA prescription and is subject to strict inventory and dispensing controls. Its use is largely restricted to hospital settings for refractory seizures, therapeutic coma, or medically assisted death in jurisdictions where permitted.
Pentobarbital vs phenobarbital — what is the difference?
Pentobarbital is a short-acting barbiturate with rapid onset and a half-life of 20–50 hours, used primarily for acute seizure control and therapeutic coma. Phenobarbital is a long-acting barbiturate with a half-life of 80–120 hours, used for chronic epilepsy management, neonatal seizures, and barbiturate withdrawal substitution. Pentobarbital has higher abuse potential and faster redistribution, while phenobarbital provides more stable, sustained anticonvulsant effect.
Why is pentobarbital contraindicated in porphyria?
Pentobarbital and other barbiturates induce the hepatic enzyme ALA synthase, which increases production of porphyrin precursors. In patients with acute intermittent porphyria or related disorders, this can precipitate a life-threatening acute porphyric attack characterized by severe abdominal pain, neuropsychiatric symptoms, motor neuropathy, and autonomic instability. Barbiturates are absolutely contraindicated in all acute hepatic porphyrias.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05CA01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.